UNSPSC 51383501: Tenidap

This classification denotes a non-steroidal anti-inflammatory agent and cyclooxygenase inhibitor with the molecular formula C14H9ClN2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9K7CJ74ONH, chemically known as 2,3-dihydro-5-chloro-2-oxo-3-(2-thienylcarbonyl)-1h-indole-1-carboxamide but generally known as tenidap, which bears US NIH Compound Identifier 57946. European Medicines Agency schedules Tenidap in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15484MIG.

UNSPSC 51383501 Tenidap is a Commodity code that captures pharmaceutical procurement by state and local government bodies, though recent solicitation activity shows the code tagged to a broader range of pharmaceutical products and services than tenidap alone — including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription program administration. State and local buyers under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida is procuring naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission is gathering vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is soliciting generic pharmaceutical and OTC product manufacturers through multi-award contracting across participating states and localities. The work involves product sourcing, pricing and compliance documentation, supply-chain coordination through authorized wholesalers, and in some cases program administration and outcomes reporting.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County's IFB60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: posted date June 30, 2026 conflicts with due date; source shows material date inconsistency). The Texas HHS Commission issued RFI HHS0017013 on March 27, 2026, with response deadline April 3, 2026, to explore vendor capabilities for direct pharmacy contracting outside traditional PBM and GPO channels. MMCAP's RFP S1070000015802 for generic pharmaceuticals and OTC products, posted January 20, 2026, with proposal deadline March 26, 2026, targets manufacturers supplying through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with awards effective July 1, 2026. Vendors must meet FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and pay a 3 percent administrative fee on contract purchases. The MMCAP RFP weighted price competitiveness at 75 percent of evaluation score, indicating cost-driven procurement across participating state and local jurisdictions.